3018 A multi-centre longitudinal study analysing disease modifying therapy prescribing patterns during the COVID-19 pandemic

Autor: Nevin John, Steve Vucic, Riadh Gouider, Tomas Kalincik, Guillermo Izquierdo, Alexandre Prat, Marc Girard, Pierre Duquette, Pierre Grammond, Serkan Ozakbas, Jeannette Lechner-Scott, Cavit Boz, Julie Prevost, Recai Turkoglu, Vincent Van Pesch, Cristina Ramo-Tello, Mark Slee, Raed Alroughani, Vahid Shaygannejad, Daniele Spitaleri, José Luis Sánchez-Menoyo, Suzanne Hodgkinson, Rana Karabudak, Tim Spelman, Helmut Butzkueven, Noriko Isobe, Paul G Sanfilippo, Michael Barnett, Orla Gray, Maria José Sá, Allan Kermode, Guy Laureys, Richard Macdonell, Anneke Van Der Walt, Ayse Altintas, Mario Habek, Pamela McCombe, Seyed Mohammad Baghbanian, Yi Chao Foong, Riki Matsumoto, Abdullah Al-Asmi, Bruce Taylor, Samia J Khoury, Todd Hardy, Katherine Buzzard, Marzena Fabis-Pedrini, Louise Rath, Olga Skibina, Jiwon Oh, William M Carroll, Katrin Gross-Paju, Jan Schepel, Sara Eichau, Elisabetta Cartechini, Aysun Soysal, Davide Maimone, Anoushka Lal, Masoud Etemadifar, Oliver Gerlach, Saloua Mrabet, Emanuele D'Amico, Yolanda Blanco, Matteo Foschi, Melissa Cambron, Andrea Surcinelli, David Levitz, Liesbeth Van Hijfte, Mehmet Fatih Yetkin, Simón Cárdenas-Robledo, Emmanuelle Lapointe, Abdorreza Naser Moghadasi, Gregor Brecl Jakob, Talal Al-Harbi

Publikováno v: BMJ Neurology Open, Vol 6, Iss Suppl 1 (2024)

Externí odkaz: https://doaj.org/article/fc8e0655ceeb42e4b6966e9c79930d0b

Longitudinal modeling of MS patient trajectories improves predictions of disability progression

Autor: De Brouwer, Edward, Becker, Thijs, Moreau, Yves, Havrdova, Eva Kubala, Trojano, Maria, Eichau, Sara, Ozakbas, Serkan, Onofrj, Marco, Grammond, Pierre, Kuhle, Jens, Kappos, Ludwig, Sola, Patrizia, Cartechini, Elisabetta, Lechner-Scott, Jeannette, Alroughani, Raed, Gerlach, Oliver, Kalincik, Tomas, Granella, Franco, GrandMaison, Francois, Bergamaschi, Roberto, Sa, Maria Jose, Van Wijmeersch, Bart, Soysal, Aysun, Sanchez-Menoyo, Jose Luis, Solaro, Claudio, Boz, Cavit, Iuliano, Gerardo, Buzzard, Katherine, Aguera-Morales, Eduardo, Terzi, Murat, Trivio, Tamara Castillo, Spitaleri, Daniele, Van Pesch, Vincent, Shaygannej, Vahid, Moore, Fraser, Guevara, Celia Oreja, Maimone, Davide, Gouider, Riadh, Csepany, Tunde, Ramo-Tello, Cristina, Peeters, Liesbet

Research in Multiple Sclerosis (MS) has recently focused on extracting knowledge from real-world clinical data sources. This type of data is more abundant than data produced during clinical trials and potentially more informative about real-world cli

Externí odkaz: http://arxiv.org/abs/2011.04749

Impact of methodological choices in comparative effectiveness studies: application in natalizumab versus fingolimod comparison among patients with multiple sclerosis

Autor: M. Lefort, S. Sharmin, J. B. Andersen, S. Vukusic, R. Casey, M. Debouverie, G. Edan, J. Ciron, A. Ruet, J. De Sèze, E. Maillart, H. Zephir, P. Labauge, G. Defer, C. Lebrun-Frenay, T. Moreau, E. Berger, P. Clavelou, J. Pelletier, B. Stankoff, O. Gout, E. Thouvenot, O. Heinzlef, A. Al-Khedr, B. Bourre, O. Casez, P. Cabre, A. Montcuquet, A. Wahab, J. P. Camdessanché, A. Maurousset, H. Ben Nasr, K. Hankiewicz, C. Pottier, N. Maubeuge, D. Dimitri-Boulos, C. Nifle, D. A. Laplaud, D. Horakova, E. K. Havrdova, R. Alroughani, G. Izquierdo, S. Eichau, S. Ozakbas, F. Patti, M. Onofrj, A. Lugaresi, M. Terzi, P. Grammond, F. Grand’Maison, B. Yamout, A. Prat, M. Girard, P. Duquette, C. Boz, M. Trojano, P. McCombe, M. Slee, J. Lechner-Scott, R. Turkoglu, P. Sola, D. Ferraro, F. Granella, V. Shaygannejad, J. Prevost, D. Maimone, O. Skibina, K. Buzzard, A. Van der Walt, R. Karabudak, B. Van Wijmeersch, T. Csepany, D. Spitaleri, S. Vucic, N. Koch-Henriksen, F. Sellebjerg, P. S. Soerensen, C. C. Hilt Christensen, P. V. Rasmussen, M. B. Jensen, J. L. Frederiksen, S. Bramow, H. K. Mathiesen, K. I. Schreiber, H. Butzkueven, M. Magyari, T. Kalincik, E. Leray

Publikováno v: BMC Medical Research Methodology, Vol 22, Iss 1, Pp 1-14 (2022)

Abstract Background Natalizumab and fingolimod are used as high-efficacy treatments in relapsing–remitting multiple sclerosis. Several observational studies comparing these two drugs have shown variable results, using different methods to control t

Externí odkaz: https://doaj.org/article/84c3797631444a10b4fb616e78d4bf21

Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

004 Pregnancy-related relapse in natalizumab, fingolimod and dimethyl fumarate-treated women with multiple sclerosis

Autor: Marco Onofrj, Dana Horakova, Pierre Duquette, Pierre Grammond, Serkan Ozakbas, Murat Terzi, Jeannette Lechner-Scott, Cavit Boz, Patrizia Sola, Franco Granella, Roberto Bergamaschi, Recai Turkoglu, Vincent Van Pesch, Raed Alroughani, Bassem Yamout, Radek Ampapa, Suzanne Hodgkinson, Helmut Butzkueven, Jim Stankovich, Albert Saiz, Michael Barnett, Richard Macdonell, Maria Pia Amato, Anneke Van Der Walt, Francesco Patti, Ayse Altintas, Pamela McCombe, Wei Z Yeh, Olga Skibina, Celia Oreja-Guevara, Tamara Castillo-Trivino, Putu A Widyastuti, Eva K Havrdova, Karolina Vodehnalova, Sara Eichau, Maria J Sá, Francois Grand’Maison, Daniele LA Spitaleri, Elisabetta Cartechini, Aysun Soysal, Melissa Gresle, Tomas Uher, Davide Maimone, Raymond MM Hupperts, Vilija G Jokubaitis, MSBase Registry

Publikováno v: BMJ Neurology Open, Vol 3, Iss Suppl 1 (2021)

Externí odkaz: https://doaj.org/article/73f419e780b84c59bc44cdd952fe9689